Allogene Therapeutics Inc (ALLO) - News Archive

Allogene Therapeutics Faces a Pivotal Moment Following the Passing of Founding Board Member David Bonderman SOUTH SAN FRANCISCO, Calif. Dec. 12, 2024 — In the corridors of Allogene Therapeutics, Inc. the news of David B...

The Promising Path of Allogene Therapeutics: Exploring Dual CAR T Cell Therapy and Pivotal TrialsAllogene Therapeutics, Inc. is at the forefront of developing allogeneic CAR T (AlloCAR T) therapies, targeting both cance...

Innovative Progress: Allogene Therapeutics Phase 1 Success in Treatment-Resistant Renal Cell Carcinoma In a vibrant stride toward advancing cancer treatment, Allogene Therapeutics, Inc. (NASDAQ: ALLO) has revealed promi...

The treatment landscape for advanced renal cell carcinoma (RCC) has evolved significantly over the past decade, yet there remains a substantial unmet need, particularly in heavily pretreated populations. Allogene Therap...

Allogene Therapeutics Inc., a leading clinical-stage biotechnology company, has made significant progress in its mission to develop innovative allogeneic CAR T-cell (AlloCAR T) products for treating cancer. The company...

Pivotal Phase 2 Trial Initiated for Cema-Cel in First Line Treatment of Large B-Cell Lymphoma Patients at High Risk of Relapse The treatment landscape for large B-cell lymphoma (LBCL) is evolving with innovative approac...

SOUTH SAN FRANCISCO, Calif., May 13, 2024 - Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company at the forefront of developing allogeneic CAR T (AlloCAR T) products for cancer and autoimmu...

Allogene Therapeutics and Arbor Biotechnologies Collaborate to Advance Allogeneic CAR T Platform in Autoimmune Disease TreatmentIn an exciting development for the field of gene editing and autoimmune disease treatment,...

proudly presents a comprehensive exploration of the strategic partnership between Allogene Therapeutics Inc., a premier clinical-stage biotechnology firm, and Foresight Diagnostics, a leading innovator of ultra-sensitiv...

Allogene Therapeutics Inc., a pioneering clinical-stage biotechnology company focused on the advancement of allogeneic CAR T (AlloCAR T) products for battling cancer, has presented detailed safety data related to its pr...